RE:RE:RE:RE:Hemophilia A potential/marketYou have very valid points . My take in terms of this investment is that we knew the pouch kind of worked with Shapiro’s study . For whatever reason, the results were preliminary. Fda trial is an important validation and milestone. We have one patient with excellent results . The market seems to think it might be one off chance, so to derisk this investment any additional patients that show promising results proves the pouch allows for vascularization and production of insulin. Another catalyst in my opinion ,to derisk this ,is collaboration with a major pharma that puts money up front . This in my opinion, would give credibilty and validation and much needed resources to move ahead with studies. The sharks know the weakness in the company is lack of resources . If they can get it for nothing , they will take it. But they also fear a competitor may take it as well. Medtronics made the mistake of doing a collaboration with an Israeli small biotech company that caused the sp to rocket which they ended up paying 1.6 Billion I think. They don’t want to make the same mistake . Medtronics has the front seat view . They see the data first , so for them to sit and do nothing might end up costing them in the end. The fact Sernova has other indications like Hemophilia and Thyroid ( which no pharma is in the field except for replacement thyroid meds) bodes well that it is more than a one trick pony. The question is management savy enough to walk the tightrope with sharks below ? Frank Hollet has been there before with some big deals before. The Fda trial for the first patient ended last April, they have to go to Fda to see what the next steps are . We have more patients implanted so we will eventually see the results, we have a collaboration with a pharma,which we have no details to. Some of these catalysts will be reavealed soon imo. And I think one of the sharks is going to become a dolfin for the investors imo. I am tired of Bioteck and his hidden motives, nobody spends this much time following the company and knows that much detail about pharma Bioteck to be flipping a few pennies. That’s why I call him out.